Related Experiment Video

Updated: Aug 19, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

22.2K

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B

Maria Ubals1,2, Pau Bosch-Nicolau3, Adrián Sánchez-Montalvá3

  • 1Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Pathogens (Basel, Switzerland)
|October 23, 2021
PubMed

Insights

Liposomal amphotericin B (L-AmB) is a promising treatment for complex cutaneous leishmaniasis (CL), showing no failures in a Spanish cohort. Close monitoring for reversible adverse events is recommended.

Area of Science:

  • Dermatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Complex cutaneous leishmaniasis (CL) lacks a definitive treatment consensus.
  • This study focuses on evaluating liposomal amphotericin B (L-AmB) outcomes in CL patients.

Purpose of the Study:

  • To describe a cohort of CL patients.
  • To evaluate the treatment outcome of liposomal amphotericin B (L-AmB) in complex CL cases.

Main Methods:

  • Retrospective study conducted at Vall d'Hebron University Hospital, Barcelona, Spain.
  • Inclusion of patients with parasitologically confirmed CL from 2012 to 2018.

Main Results:

  • 41 CL patients analyzed; 17 had complex CL requiring systemic treatment.
  • 16 patients received L-AmB; 50% experienced adverse events, 19% discontinued treatment due to safety.
  • All L-AmB treated cases achieved cure within one year post-treatment.

Conclusions:

  • L-AmB demonstrated no treatment failures in complex CL, presenting a viable alternative.
  • Vigilant monitoring for L-AmB's potential adverse events is crucial for managing reversible side effects.
Abstract

Keywords:
complex cutaneous leishmaniasiscutaneous leishmaniasisleishmanialiposomal amphotericin Bsystemic therapy

More Related Videos

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line12:22

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

22.6K
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

8.4K

Related Concept Videos

Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...